Compare INDB & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INDB | ERAS |
|---|---|---|
| Founded | 1907 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.0B |
| IPO Year | 1994 | 2021 |
| Metric | INDB | ERAS |
|---|---|---|
| Price | $85.94 | $18.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $87.00 | $14.25 |
| AVG Volume (30 Days) | 359.1K | ★ 3.7M |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 3.33 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.83 | N/A |
| Revenue Next Year | $5.85 | N/A |
| P/E Ratio | $25.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $63.33 | $1.33 |
| 52 Week High | $87.50 | $24.28 |
| Indicator | INDB | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 50.90 |
| Support Level | $76.40 | $17.36 |
| Resistance Level | $86.78 | $19.96 |
| Average True Range (ATR) | 1.38 | 1.02 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 75.70 | 53.27 |
Independent Bank Corp is a bank holding company and the sole shareholder of its bank, the Rockland Trust Company. Rockland is a community-oriented commercial bank. The bank provides a variety of banking, investment and financial services, operating with various retail branches, as well as a network of commercial and residential lending centers and investment management offices majorly in Eastern Massachusetts, Worcester County, and Rhode Island. The bank's loan portfolio constitutes the bulk of the bank's total assets. Its borrowers consist mostly of small to medium-size businesses and consumers, majority of which are made to its market area in eastern Massachusetts and Rhode Island. The bank's loan portfolio is predominantly in commercial loans.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.